Compare Merck & Co., Inc. (MRK) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Merck & Co., Inc. trades at $146.19 (market cap $351.28B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.88 (market cap $3.56B). The key difference: Merck & Co., Inc. is far larger — about 98.7× GraniteShares 2x Long NVDA Daily ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| MRK | NVDL | |
|---|---|---|
Market Cap | $351.28B | $3.56B |
Volume | 7,969,665 | 9,740,643 |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $43.02 |
52-Week Low | $82.49 | $21.76 |
Typical Hold Time | 98 Days | 15 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.905, down 6.73% on the day, with technical indicators showing a bullish bias from moving averages but neutral oscillators. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to lead AI innovation and recently beat Q2 2027 earnings estimates. Support levels are clustered around $36-$34, with resistance at $38-$41.
While leveraged exposure to NVIDIA's AI leadership offers significant upside potential, NVDL faces risks from daily reset mechanics that can cause performance drift from long-term NVDA returns. Recent articles highlight both optimism about NVIDIA's technical breakout and concerns about the ETF's tracking efficiency. The bullish technical setup suggests near-term opportunity, but volatility remains elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
